For many years when attending radiopharmaceutical chemistry-related meetings and reviewing abstracts and papers, I have not always found it easy to reconstruct what the authors exactly mean in their results sections. Are the reported radiochemical yields decay corrected or not? If so to what timepoint? A number of papers have used terms ‘radiochemical conversion’. However, different groups seem to define this in slightly different ways, and others not at all. Furthermore, how should we use superscripts for radionuclide descriptors? Square brackets, no brackets, hyphens? And the list goes on ……

Recognising the increasing challenge in trying to understand radiochemistry communications, the Drug Development Committee of the EANM composed a working group together with representatives of many relevant societies including EANM, SNMMI, SRS and national nuclear medicine societies 2 years ago with the aim to generate consensus on how to use scientific radiochemistry terms/nomenclature and when (or not) to use them. The working group has now published a consultation document on radiochemistry nomenclature good practice and are requesting the radiopharmaceutical chemistry community to review this and feedback by 31st January 2017 in order to finalise the consensus nomenclature document.

I would like to draw your attention to this important initiative and encourage you to read the documents and provide feedback. This initiative will help to enable unambiguous communication in our field. The consultation document and call for feedback can be found on the following link: http://www.srsweb.org/nomenclature-guidelines/

Editor-in-Chief, Philip Elsinga

Affiliations

1. University of Groningen, Groningen, Netherlands

   Philip H. Elsinga

Authors

1. Philip H. ElsingaView author publications

   You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip H. Elsinga.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

Cite this article

Elsinga, P.H. Nomenclature for radiopharmaceuticals, consultation of your opinion!. EJNMMI radiopharm. chem. 2, 1 (2017). https://doi.org/10.1186/s41181-017-0022-z

Download citation

• Received: 04 January 2017

• Accepted: 05 January 2017

• Published: 18 January 2017

• DOI: https://doi.org/10.1186/s41181-017-0022-z

中文翻译：

---

放射性药物的命名，请咨询您的意见！

多年来，在参加与放射性药物化学相关的会议并审阅摘要和论文时，我并不总是很容易就能轻松地重构出作者在其结果部分中的确切含义。报告的放射化学产量衰减是否得到纠正？如果是，到什么时间点？许多论文使用了术语“放射化学转化”。但是，不同的组似乎以略有不同的方式定义了此定义，而其他组则完全没有。此外，我们应该如何对放射性核素描述符使用上标？方括号，无括号，连字符？而这样的例子不胜枚举 ……

认识到试图理解放射化学通讯方面的挑战日益严峻，EANM药物开发委员会与许多相关协会（包括EANM，SNMMI，SRS和国家核医学协会）的代表组成了一个工作组，目的是在两年前达成共识如何使用科学的放射化学术语/术语，以及何时（或不使用）它们。工作组现已发布了有关放射化学命名法良好做法的咨询文件，并要求放射性药物化学界在2017年1月31日之前对此进行审查并提供反馈意见，以最终确定共识性命名文件。

我想提请您注意这一重要举措，并鼓励您阅读文档并提供反馈。该倡议将有助于实现我们领域内的明确沟通。咨询文件和要求反馈的信息可以在以下链接中找到：http : //www.srsweb.org/nomenclature-guidelines/

菲利普·埃尔辛加（Philip Elsinga）主编

隶属关系

1. 格罗宁根大学，荷兰格罗宁根

   菲利普·H·埃尔辛加

作者

1. Philip H. Elsinga查看作者出版物

   您也可以在PubMed Google学术搜索中搜索该作者 

通讯作者

与Philip H. Elsinga的往来。

开放获取本文是根据知识共享署名4.0国际许可（http://creativecommons.org/licenses/by/4.0/）的条款分发的，该许可允许您以任何方式在任何介质中进行无限制的使用，分发和复制。适当的版权归原始作者和来源，提供指向知识共享许可的链接，并指出是否进行了更改。

转载和许可

引用本文

Elsinga，PH放射性药物的命名，请咨询您的意见！EJNMMI放射性药物。化学 2，1（2017）。https://doi.org/10.1186/s41181-017-0022-z

下载引文

• 收到：2017年1月4日

• 已接受：2017年1月5日

• 发表时间：2017年1月18日

• DOI ：https：//doi.org/10.1186/s41181-017-0022-z